Haleon launches buyback and hikes dividend after strong year healthcare Consumer healthcare giant Haleon has reported a strong financial performance for 2024, with organic revenue growth of five per cent. However, revenue declined by 0.6 per cent on a reported basis to £11.2bn, while adjusted operating profit increased 9.8 per cent to £2.5bn. Haleon focuses on over-the-counter medicines, oral health, and vitamins, minerals and supplements. [...]
Sensodyne and ‘power brands’ help Haleon grow revenue and profit Retail Consumer healthcare company Haleon has reported growth across all its categories and regions in its third quarter amid healthy toothpaste and mouthwash sales. In the three months ended 30 September, 2024, it achieved organic revenue and organic profit growth of 6.1 per cent and 7.4 per cent, respectively, off the back of strong sales of its [...]
Haleon posts profit bump on back of power brands Business Consumer healthcare company Haleon has reported mid-single-digit growth amid strong demand for its power brands despite a soft market.
Haleon: Sensodyne maker strikes £500m deal to sell major division June 26, 2024 Haleon, the maker of Sensodyne toothpaste, has agreed a £500m deal to sell a major division outside of the US.
Haleon posts healthy first quarter update after UK job cuts May 1, 2024 Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
Sensodyne maker Haleon to cut over 400 jobs and close its only UK factory April 30, 2024 The maker of Sensodyne toothpaste and Advil painkillers has announced plans to close its only UK factory which will see the loss of more than 400 jobs.
Panadol painkiller-maker Haleon to buy shares from Pfizer as US pharma giant slims stake March 18, 2024 fizer has committed to sell down its stake in a "slow and methodical" manner over time.
Haleon reports single-digit growth in revenue after year of disposals February 29, 2024 Its revenue went up by four per cent from £10.8bn reported in 2022, as the company's adjusted operating profit had a healthy growth of 10.4 per cent, at constant currency to £2.5bn.
GSK spin-off Haleon offloads Chapstick brand for £400m to ‘simplify’ business January 25, 2024 Consumer healthcare company Haleon has agreed to sell its Chapstick lip balm brand to Yellow Wood Partners in a deal worth $510m (£401m) as part of efforts to "simplify" its business model.
Haleon: Chinese re-opening powers GSK spin-off to ‘consistent’ growth August 2, 2023 Strong sales of toothpaste and painkillers contributed to healthy results for Haleon, the newly-formed consumer healthcare firm spun out of GSK last year. In the first half of 2023, the Surrey-headquartered company’s revenue increased to £5.7bn, up 10.6 per cent compared to the same period last year. This was driven by Haleon’s ‘power brands’, such [...]